Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for Visual Recovery After Ischemic Stroke
NCT02737930Phase 2Terminated
- Start
- May 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in visual field loss (VFD) comparing Fluoxetine with Placebo (2 arms). Primary endpoint: Percent Change in the Bionocularly Averaged Perimetric Mean Deviation at 6 months. Started May 2016; status: terminated.
02
Drugs
fluoxetine
03
Conditions
visual field loss (VFD)
Beyond the preview
Go deeper on NCT02737930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737930.